Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

The lung cancer diagnostics market encompasses tools, techniques, and services for detecting lung cancer, including imaging, ...

“Taletrectinib is a highly selective, next-generation oral tyrosine kinase inhibitor, with the potential to expand what’s possible for patients with ROS1-positive non-small cell lung cancer ...

Doctors debunk persistent cancer myths-from sugar and deodorants to breast surgery and mobile phones-that often mislead patients, delay diagnosis, and derail treatment decisions ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2025, and ...

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a matching-adjusted indirect ...

The Canadian Council of Insurance Regulators (CCIR) is pleased to announce the release of its Position Paper on the Harmonization of Incident Reporting ...

“Taletrectinib is a highly selective, next-generation oral tyrosine kinase inhibitor, with the potential to expand what’s possible for patients with ROS1-positive non-small cell lung cancer,” said ...

Precision Oncology market is set for strong growth through 2035, fueled by genomic advances, rising cancer cases, and increased use of targeted therapies.